HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: An analysis from the JUPITER trial
Paul M. Ridker, Jacques Genest, S. Matthijs Boekholdt, Peter Libby, Antonio M. Gotto, Børge G. Nordestgaard, Samia Mora, Jean G. MacFadyen, Robert J. Glynn, John J P Kastelein
Dive into the research topics of 'HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: An analysis from the JUPITER trial'. Together they form a unique fingerprint.